Takeda Partners to Develop Anti-Inflammatory Treatment

Takeda, a Council member, is partnering with ProThera Biologics Inc. to develop a treatment for acute inflammatory conditions.

Under a new global licensing agreement, Takeda will be responsible for the commercial activities and development of the treatment. ProThera is researching a plasma-derived therapy that would replenish naturally occurring proteins that reduce inflammation in the body. Together the companies will explore treatments such as the Inter-alpha Inhibitor Proteins therapy, as well as companion diagnostics to determine the effectiveness of the therapy in a real-world setting.

“We believe ProThera’s expertise in IAIP technology represents a potentially powerful opportunity to explore the untapped potential of plasma in order to address challenging rare and complex diseases,” commented Dr. Chris Morabito, Takeda’s Head of Research and Development, Plasma-Derived Therapies Business Unit. “Leveraging this potent technology using our deep expertise and robust dedicated plasma infrastructure, this collaboration reflects our patient-centered R&D efforts and could represent an important new avenue to deliver meaningful innovation to patient populations in need.”

NEC congratulates ProThera and Takeda on their innovative research. Read more from Takeda and Providence Business News.